Grail, Inc.(US:GRAL) Financial Modeling Prep·2026-02-20 18:09Core Insights - Grail Inc. is a biotechnology company focused on early cancer detection, particularly through its multi-cancer screening test, Galleri, which aims to identify cancer at early stages [1] - The company operates in a competitive landscape with other biotech firms also striving for advancements in cancer diagnostics [1] Stock Performance - On February 20, 2026, Canaccord Genuity set a new price target of $80 for Grail, indicating a potential downside of approximately -21.21% from the stock's trading price of $101.53 at that time [2] - Grail's stock has experienced a dramatic plunge of 50% following disappointing results from a U.K. trial of Galleri, which did not achieve a statistically significant reduction in stage 3 and 4 cancer cases [3] - Currently, Grail's stock is priced at $101.53, reflecting a decrease of 0.75, or -0.73% [4] - Over the past year, Grail's stock has shown significant volatility, reaching a high of $118.84 and a low of $20.44 [4] Market Capitalization and Trading Volume - Grail's market capitalization is approximately $3.96 billion, with a trading volume of 1,545,372 shares on the NASDAQ exchange [5] - Recent developments and the price target adjustment by Canaccord Genuity highlight the challenges Grail faces in regaining investor confidence and stabilizing its stock performance [5]